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1. Introduction 
Venous vascular extension is one of the aggressive tumor behaviors especially for renal cell 
carcinoma (RCC). It has been reported that 4% to 10% have tumor thrombus extending into 
the venous system among patients with newly diagnosed RCC (Marshall et al., 1970; Hoehn 
& Hermanek, 1983; Casanova & Zingg, 1991; Hatcher et al., 1991; Pagano et al., 1992). 
Compared with conservative treatment regimens, surgical resection remains the most 
effective treatment for these patients (Staehler & Brkovic, 2000). The mean 5-year survival 
rates of such patients with inferior vena cava involvement undergoing radical surgery for 
RCC have been reported as 32% to 64% (Neves & Zincke, 1987; Skinner et al., 1989; Montie 
et al., 1991; Swierzewski et al., 1994; Glazer & Novick, 1996). 
Since the introduction of the tumor, node, metastasis (TNM) staging system, the pathologic 
stage has been considered the most important prognostic factor in RCC. According to the 
2002 American Joint Committee on Cancer (AJCC) TNM staging classification (Greene et al., 
2002), pT3 RCCs are subclassified into tumors invading perirenal fat and/or the ipsilateral 
adrenal gland (2002-pT3a), those presenting with tumor thrombus within the renal vein or 
the vena cava below the diaphragm (2002-pT3b) and those with vena cava thrombus above 
the diaphragm (2002-pT3c). This classification was very recently modified in 2009 (Edge et 
al., 2009), modified subclassification of pT3 RCCs are defined as tumors grossly extending 
into the renal vein or its segmental branches, or tumors invading perirenal and/or renal 
sinus fat but not beyond Gerota’s fascia (2009-pT3a), those presenting with tumor thrombus 
within the vena cava below the diaphragm (2009-pT3b) and those with vena cava thrombus 
above the diaphragm or invaded the wall of the vena cava (2009-pT3c). 
It has been debated that the TNM classification needs improvement in order to provide 
prognostic accuracy (Thompson et al., 2005; Leibovich et al., 2005; Ficarra et al., 2007). 
Several studies have discussed the correlation between prognosis and level of venous 
extension (Hatcher et al., 1991; Ljungberg et al., 1995; Tongaonkar et al., 1995; Glazer & 
Novick, 1996; Kuczyk et al., 1997; Staehler & Brkovic, 2000; Kim et al., 2004; Moinzadeh & 
Libertino, 2004). However, the prognostic impact of perirenal fat or adrenal gland 
involvement – based on the tumor characteristics of 2002 AJCC TNM staging classification 
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T1: Tumor 7 cm or less in greatest 
dimension, limited to the kidney 
 
T1a: Tumor 4 cm or less in greatest 
dimension, limited to the kidney 
T1b: Tumor more than 4 cm but not more 
than 7 cm in greatest dimension, limited to 
the kidney 
T1: Tumor 7 cm or less in greatest 
dimension, limited to the kidney 
 
T1a: Tumor 4 cm or less in greatest 
dimension, limited to the kidney 
T1b: Tumor more than 4 cm but not more 
than 7 cm in greatest dimension, limited to 
the kidney 
 
T2: Tumor more than 7 cm in greatest 
dimension, limited to the kidney 
 
 
T2: Tumor more than 7 cm in greatest 
dimension, limited to the kidney 
 
T2a: Tumor more than 7 cm but less than 
or equal to 10 cm in greatest dimension, 
limited to the kidney 
T2b: Tumor more than 10 cm, limited to 
the kidney 
 
T3: Tumor extends into major veins or 
invades adrenal gland or perinephric 
tissues but not beyond Gerota’s fascia 
 
 
T3a: Tumor directly invades adrenal gland 
or perirenal and/or renal sinus fat but not 
beyond Gerota’s fascia 
T3b: Tumor grossly extends into the renal 
vein or its segmental (muscle-containing) 
branches, or vena cava below the 
diaphragm 
T3c: Tumor grossly extends into the vena 
cava above the diaphragm or invades the 
wall of the vena cava 
 
T3: Tumor extends into major veins or 
perinephric tissues but not into the 
ipsilateral adrenal gland and not beyond 
Gerota’s fascia 
 
T3a: Tumor grossly extends into the renal 
vein or its segmental (muscle containing) 
branches, or tumor invades perirenal 
and/or renal sinus fat but not beyond 
Gerota’s fascia 
T3b: Tumor grossly extends into the vena 
cava below the diaphragm 
T3c: Tumor grossly extends into the vena 
cava above the diaphragm or invades the 
wall of the vena cava 
 
T4: Tumor invades beyond Gerota’s fascia 
 
 
T4: Tumor invades beyond Gerota’s fascia 
(including contiguous extension into the 
ipsilateral adrenal gland) 
Table 1. AJCC primary tumor staging classification of RCC 
(2002-pT3a) – has not been seriously examined in patients with RCC exhibiting venous 
vascular extension. We hypothesized that RCC exhibiting venous vascular extension 
represents passive invasive features, since the low blood pressure in the renal vein allows 
tumors to easily extend into the venous system without aggressive characteristics, while 
perirenal fat or adrenal gland involvement represents active invasive features. Thus in this 
chapter, we describe the prognostic impact of perirenal fat or adrenal gland involvement in 
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patients with RCC exhibiting venous vascular extension and the proposal for reclassification 
of the current TNM staging. 
2. RCC exhibiting venous vascular extension 
Forty-three patients with RCC exhibiting venous vascular extension entirely below the 
diaphragm were evaluated. Patients were treated by radical nephrectomy with complete 
resection of tumor thrombus extending into the venous system. Venous extension was 
defined as gross involvement. The patients included 35 males and 8 females, with median 
age at surgery of 62 years (range 43-82 years). The median tumor size was 8.79 cm (range 
2.3-17.0 cm). The tumor site was on the right in 20 cases and on the left in 23 cases. 
All patients received a preoperative evaluation that included routine blood test, chest x-rays, 
ultrasonography, and computerized tomography (CT), magnetic resonance imaging, or 
both. They then underwent radical nephrectomy with complete resection of the tumor and 
thrombus. Regional lymphadenectomy was performed concurrently with the radical 
nephrectomy. Postoperative evaluations, performed at intervals of 1 to 3 months, included 
blood test, chest x-rays, and CT. Bone scans were obtained when indicated. Hospital charts 
were retrospectively reviewed, and patient status was ascertained via office visit or 
telephone call to the patient. 
All histological samples were reviewed by a single pathologist and were defined as tumor 
thrombus only or as tumor thrombus with perirenal fat or adrenal gland involvement. 
Nonparametric estimates of survival were performed using Kaplan-Meier curves. Survival 
curves were generated based on disease-specific survival, representing patients still alive at 
specified intervals from the time of surgery to the date of death or the last follow-up visit. 
Log-rank tests were used for statistical comparisons. 
Differences in identified prognostic parameters between tumor thrombus only and tumor 
thrombus with perirenal fat or adrenal gland involvement were analyzed using t test and 
chi-square test. Survival analysis regression model was assessed by Cox proportional 
hazards model to estimate the relative importance of the variables. 
Additionally, nonparametric Kaplan-Meier survival estimates were performed to compare 
perirenal fat or adrenal gland involvement only (2002-pT3a), tumor thrombus only, and 
tumor thrombus with perirenal fat or adrenal gland involvement. The perirenal fat or 
adrenal gland involvement only (2002-pT3a) cohort represented 65 cases with complete 
resection of the tumor. Survival curves and log-rank tests were analyzed. 
3. Prognostic impact of perirenal fat or adrenal gland involvement 
3.1 Patient characteristics 
The tumor thrombus only cohort included 21 males and 2 females (total 23 patients; 53.5%) 
with a median age of 61 years (range 44-78 years) and median follow-up period of 37 
months (range 2-106 months). The median tumor size was 9.0 cm (range 2.3-17.0 cm); tumor 
site was on the right in 10 cases and on the left in 13 cases. 
The tumor thrombus with perirenal fat or adrenal gland involvement cohort included 14 
males and 6 females (total 20 patients; 46.5%) with a median age of 64 years (range 43-82 
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years) and median follow-up period of 9.5 months (range 2-45 months). The median tumor 
size was 8.45 cm (range 4.0-16.0 cm); tumor site was on the right in 10 cases and on the left 
in 10 cases. 
When several parameters were analyzed for differences between tumor thrombus only 
cohort and tumor thrombus with perirenal fat or adrenal gland involvement cohort using t 
test or chi-square test, two parameters – Eastern Cooperative Oncology Group (ECOG) 
performance status (PS) 0 and histological grade 3 – proved statistically significant (P = 
0.0329 and 0.0377, respectively; chi-square test). 
 
Characteristic Tumor thrombus only
Tumor thrombus with 
perirenal fat or adrenal 
gland involvement 
P Value 
Patients (n) 23 20  
Follow-up period (month)    
Median 37 9.5  Range 2-106 2-45 
Age $ (year)    
Median 61 64  Range 44-78 43-82 
Mean  SE 60.1  1.9 64.3  2.3 0.1673 
Gender (n)    
Male 21 14 0.1180 Female 2 6 
Tumor diameter $ (cm)    
Median 9.0 8.45  Range 2.3-17.0 4.0-16.0 
Mean  SE 9.0  0.9 8.3  0.8 0.5240 
Tumor site (n)    
Right 10 10  Left 13 10 
ECOG PS 0 * (n) 15 6 0.0329 
Initial symptom (n) 21 16 0.3929 
Preoperative metastasis (n) 5 8 0.3184 
Grade 3 * (n) 1 6 0.0377 
pN (n) 1 5 0.0814 
Clear cell (n) 21 14 0.1180 
Spindle cell (n) 0 3 0.0924 
KEY: ECOG PS = Eastern Cooperative Oncology Group performance status. 
$ Analysis assessed by t test. 
* Statistically significant. 
Table 2. Patient characteristics and comparison among groups 
3.2 Kaplan-Meier survival analysis 
Nonparametric survival was analyzed by Kaplan-Meier survival curves, plotting both 
tumor thrombus only and tumor thrombus with perirenal fat or adrenal gland involvement. 
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Mean disease-specific survival time for patients with tumor thrombus with perirenal fat or 
adrenal gland involvement was 25.0  4.4 (SE) months. On the other hand, mean survival 
time for those with tumor thrombus only was significantly longer at 70.9  9.1 (SE) months 
(P = 0.0032, Fig. 1). 
 
Fig. 1. Kaplan-Meier disease-specific survival after nephrectomy 
 
Fig. 2. Kaplan-Meier disease-specific survival after nephrectomy for those with perirenal fat 
or adrenal gland involvement only (2002-pT3a) 
www.intechopen.com
 
Emerging Research and Treatments in Renal Cell Carcinoma 
 
294 
Mean disease-specific survival time for patients with perirenal fat or adrenal gland 
involvement only (2002-pT3a) was longer still at 116.1  12.3 (SE) months. This value is 
significantly longer than for those with tumor thrombus with perirenal fat or adrenal gland 
involvement (P = 0.0044, Fig. 2), but not statistically significant different from that for those 
with tumor thrombus only. 
3.3 Cox proportional hazards regression analysis 
Univariate Cox proportional hazards regression analysis was performed for each variable. 
Significantly shorter disease-specific survival after surgery was predicted by presence of 
perirenal fat or adrenal gland involvement (P = 0.0065), preoperative metastasis (P = 0.0025), 
surgical specimens positive for lymph node metastasis (P = 0.0183), and spindle cell factor 
(P = 0.0233). 
 
Variable Hazard Ratio 95% CI P Value 
Perirenal fat or adrenal gland 
involvement * 4.11 1.4911.4 0.0065 
ECOG PS 0 1.34 0.543.34 0.5303 
Initial symptom 2.13 0.2816.2 0.4639 
Preoperative metastasis * 4.32 1.6811.2 0.0025 
Tumor diameter 1.03 0.901.17 0.6984 
Grade 3 0.34 0.111.11 0.0732 
pN * 0.30 0.110.81 0.0183 
Clear cell 1.76 0.575.39 0.3248 
Spindle cell * 0.16 0.030.78 0.0233 
KEY: CI = confidence interval; ECOG PS = Eastern Cooperative Oncology Group performance status. 
* Statistically significant. 
Table 3. Univariate analysis by Cox proportional hazards model 
4. Prognostic factors for RCC exhibiting venous vascular extension 
Although the pathologic stage highly correlates with outcome in patients with RCC, the 
prognosis may vary even among tumors of the same stage. Thus, additional prognostic 
factors are needed. For RCCs exhibiting venous vascular extension, several investigators 
have described the prognostic significance of the level of venous extension (Hatcher et al., 
1991; Ljungberg et al., 1995; Tongaonkar et al., 1995; Glazer & Novick, 1996; Kuczyk et al., 
1997; Staehler & Brkovic, 2000). Most recent series have reported that the level of tumor 
thrombosis in the inferior vena cava does not significantly effect long-term survival (Kim et 
al., 2004; Moinzadeh & Libertino, 2004). Local tumor stage and grade are better predictors of 
prognosis than extent of venous involvement (Kim et al., 2004), but the most significant 
factors for survival in patients with RCC exhibiting venous vascular extension are still 
unknown. 
The impact of perirenal fat or adrenal gland involvement in patients with RCC exhibiting 
venous vascular extension has not been seriously examined. Only the impact of perirenal fat 
involvement on prognosis of RCC patients has been documented (Gettman et al., 2003). On 
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multivariate analyses, perirenal fat involvement led to a significantly worse prognosis, as 
did histological grade and metastasis (Gettman et al., 2003). However, perirenal fat 
involvement cannot be simply categorized, given the data we present here for the category 
of tumor thrombus with perirenal fat or adrenal gland involvement. This is the first 
investigation to specifically examine RCCs exhibiting tumor thrombus with perirenal fat or 
adrenal gland involvement and suggest that they represent a separate subcategory. 
Tumor thrombus with perirenal fat or adrenal gland involvement has shorter disease-
specific survival time than tumor thrombus only, or perirenal fat or adrenal gland 
involvement only (2002-pT3a). Tumors that are both tumor thrombus and perirenal fat or 
adrenal gland involvement are not the same as those that are only tumor thrombus. If 
patients with tumor thrombus also have perirenal fat or adrenal gland involvement, the 
prognosis is significantly poorer. The 5-year disease-specific survival estimate for tumor 
thrombus only was 65%, while that for tumor thrombus with perirenal fat or adrenal gland 
involvement was 0%. On univariate analyses, perirenal fat or adrenal gland involvement, 
preoperative metastasis, positive lymph node metastasis, and spindle cell factor were 
significant predictors of poor prognosis. Metastatic disease has been reported as an adverse 
predictor of disease-specific survival by several investigators (Neves & Zincke, 1987; 
Hatcher et al., 1991; Swierzewski et al., 1994; Tongaonkar et al., 1995; Nesbitt et al., 1997; 
Gettman et al., 2003). Generally, histological grade is identified as an independent 
prognostic factor in all RCCs (Méjean at al., 2003), but our results suggest histological grade 
does not affect survival in patients specifically having RCCs exhibiting tumor thrombus 
with perirenal fat or adrenal gland involvement. 
5. Adrenal gland involvement in RCC 
Patients with adrenal gland involvement have significantly worse survival than those with 
perirenal fat involvement (Han et al., 2003; Siemer et al., 2005). Direct ipsilateral adrenal 
gland involvement in RCC is rare, found in only 2.5% of radical nephrectomy specimens, 
and representing 13% of all 2002-pT3a lesions (Han et al., 2003). In this study, there were too 
few patients with RCCs exhibiting tumor thrombus with perirenal fat or adrenal gland 
involvement to allow a comparison of survival for patients with adrenal gland or perirenal 
fat involvement. However, previous investigators have emphasized that adrenal gland 
involvement should reclassified because of the worse prognosis (Han et al., 2003; Siemer et 
al., 2005; Fujita et al., 2008). According to the 2002 AJCC TNM staging classification (Greene 
et al., 2002), pT4 RCC is defined as tumor invades beyond Gerota’s fascia. The median 
disease-specific survival for patients with ipsilateral adrenal gland involvement was 
significantly worse than that for tumor infiltrating only the perirenal fat and was similar to 
that for patients with 2002-pT4 RCCs (Han et al., 2003). The 5-year disease-specific survival 
probabilities have been reported 20.2% (Thompson et al., 2005) and 0% (Fujita et al., 2008). 
Primary adrenal carcinoma that invades the kidney is classified as pT4 disease (Ng & 
Libertino, 2003; Norton et al., 2005). A number of previous reports have suggested that, 
analogously, RCC with adrenal gland involvement should be reclassified as 2002-pT4 
(Sandock et al., 1997; Han et al., 2003; Siemer et al., 2005; Thompson et al., 2005). Based on 
these investigations, adrenal gland involvement has been classified pT4 in 2009 AJCC TNM 
staging classification (Edge et al., 2009). 
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6. Proposal for reclassification of the TNM staging 
According to a commentary by the Union Internationale Contre le Cancer (UICC) regarding 
continuous improvement of the TNM classification, the criteria for instituting changes 
include clinical relevance for assessment, treatment and outcome, presence of evidence for 
improved prognostic ability, and acceptance by the members of the UICC TNM committee 
(Gospodarowicz et al., 2004). The 2002 AJCC TNM system for patients with pT3 RCC 
incorporates the features of tumor thrombus, perirenal fat invasion and direct ipsilateral 
adrenal gland involvement (Greene et al., 2002). Several studies addressing 2002-pT3 
staging have been reported and debated (Thompson et al., 2005; Leibovich et al., 2005; 
Ficarra et al., 2007; Fujita et al., 2008). And very recently, AJCC TNM staging classification 
was updated (Edge et al., 2009). However, tumor thrombus with perirenal fat or adrenal 
gland involvement was not well included in this modification. The prognosis of patients 
with tumor thrombus with perirenal fat or adrenal gland involvement was poor, as well as 
adrenal gland involvement which was subclassified as pT4 in 2009 AJCC TNM classification 
(Fujita et al., 2008; Edge et al., 2009). Reclassification will be still needed for tumor thrombus 
with perirenal fat or adrenal gland involvement RCCs. Reclassification of the current TNM 
staging system for RCCs according to the available clinical data and in accordance with the 
proposed process to update the staging system will render it a more powerful tool for 
predicting patient outcomes (Ficarra et al., 2006). The resultant staging system should be 
intended to give prognostic information that will allow accurate patient counseling, 
therapeutic selection, and surveillance (Howard & Wood, 2006). Our suggested revisions to 
the TNM classification represent a significant improvement in its prognostic accuracy. 
7. Conclusion 
The presence of perirenal fat or adrenal gland involvement in patients with RCC exhibiting 
venous vascular extension entirely below the diaphragm leads to a significantly poorer 
prognosis. Presence of perirenal fat or adrenal gland involvement is important for such 
cases and calls for active investigation. Additionally, reclassification will be needed for 
tumor thrombus with perirenal fat or adrenal gland involvement RCCs. 
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